 Good morning, Erica and Guillermo. How are you? Hi, good morning. Good morning. Good morning. I see Dennis on the call. Great to have you on the call, Dennis. Thank you. Good morning, everybody. Good morning, everyone. Good morning. Yeah. So I do suspect that we're going to have quite a number of folks on the call. I suspect they'll be dialing in, but I do want to get started. It is the top of the hour and we have a good conversation, I think, queued up. So let's just get started. So first and foremost, as always, just a reminder that this is a recorded call. So please refrain from any IP or discussions that are proprietary as well. I want to just move us over to our antitrust slide. And here's our policy notice. Please follow the URL here. If you want to get details on it, what the upshot is, please be a good person and behave well. So this is a special topic meeting. And so we're going to sort of foreshorten some of the general introductions. But I do want to have anyone that's on the call that wants to introduce themselves. Please feel free to do so now. Anyone on the call want to say hello? Hello, Alfonso Grovela from Merida and Yucatan, Mexico. Happy to be with you. Hyperledger Merida. Oh, excellent. Thank you, Alfonso. Good morning to you. Great to have you on the call. Phenomenal that we're getting some very interesting sort of diversity here. And I'm glad to have that today, particularly in fact, Guillermo will be speaking a little bit about sort of the state of Mexico. So we also, it sounds like we have Central America as well. And then just in general, we'll probably be doing sort of a quick go-around because I know that Dennis is on the call. And Dennis from Switzerland will give us a status on the EU. And I do know Dennis needs to sort of jump off the call about a quarter after the hour. So we're going to be moving right over to that in just a very short period of time. If there's anyone else on the call that wants to introduce themselves before we get started, and thank you Alfonso for that. Hey there, this is Heather Flannery. I'm the CEO of Consensus Health. Delighted to be here. Great to see a number of friends and colleagues on the line. And thank you for the warm welcome, Rich. Great to have you, Heather. Great to have you. Phenomenal, thank you. Yeah, this will be a very good, I think, good conversation as sort of a follow-on from what we were sort of kicking off yesterday in some separate conversations. Anyone else? Yeah, go ahead. This is Alex Posting with CTO for Hashtag Health. Oh, hi, Alex. How are you doing today, Rich? Great to have you. Thanks for joining us. Appreciate it. Absolutely. Looking forward to it. I'm going to be on mute. If anything comes up, I'll just come off mute. Perfect. Sounds very good. And just as a general sort of roll of thumb, I'm working out of our home office. And so if we do have any internet issues, it may be on my side. We sort of live in a roll part of Snohomish, which is about an hour or so north of Seattle. So it is beautiful out here right now, but it's remote. OK, with that started, anyone else in the call? Otherwise, we'll just dive right into it. All righty. OK, well, so as I mentioned before, this is a special topic meeting. And we are sort of focused on the COVID-19 virus. Really, the purpose of the call is initially a sort of a follow on from two weeks ago, our last general meeting. When I put this on the agenda as a topic, and it just fell off because of time constraints. And so I wanted to sort of recycle this. And of course, in the past two weeks, it's certainly grown significantly. And it is obviously sort of a focus for many of us, even outside of the health care industry. And so this is such a significant issue. At least in my mind, we have about 1,000 members in the HCCIG. And in my mind, and these are all global professionals, this is a great opportunity for us to sort of get together and think at a very broad level about how we might approach solving some of the issues that are collateral to the COVID-19 virus. And just sort of a note, I sort of frame this in using blockchain technologies. But I don't want to certainly think in terms of limiting any kind of decisions or thoughts or ideation around having, qualifying the use of blockchain. It just so happens that those of us that are around the call today are pretty facile when it comes to using blockchain technologies. But I don't want to limit or sort of blind ourselves to other ideas or solutions that may or may not use blockchain technologies. So this is a very large sort of ideation exercise. And so just sort of to kick it off, so we're thinking in terms of how we might be able to use blockchain technologies sort of briefly to solve or to offset some of the issues surrounding COVID-19. And before I wanted to get into that, I did want to have an opportunity to sort of take a quick tour around the globe. We do have some of our members that are from other parts of outside of the US. And so I wanted to sort of have them present a little bit on where they are in respect to what their observations are and thoughts are as it relates to their particular place. And so I'm going to hand this over to Dennis. Dennis Koskin is the chair of our HE sick patients subgroup. He happens to live in Switzerland. And so he's going to sort of give us a kind of a thumbnail report on what his observations are from his perspective living in Switzerland. And then we're going to sort of segue over to Guillermo Diaz who happens to live in Mexico. He's one of our members for the healthcare interoperability subgroup. So Dennis, I'll hand it over to you. Thank you very much Rich. It's very kind of you asking my feedback and having the opportunity giving a reflection from Europe, from Switzerland. First thing, it's a very much weird feeling. The French border is closed. It's almost 15 kilometers away from me. Custom driving thousands of miles in Europe and just jailed at the moment. And other thing is, I think I was infected and I had the first symptoms of that. And after five days, I recovered quickly and also my wife. The thing is, it is really not influencia. It's very much different and it's very uncomfortable. This is the reflection as a patient. And I see also the many of the European countries, Switzerland is very much late in reacting against the epidemic and not the pandemic. There are reasons and the result is bigger economics low down at the end. And there's also not the best information management. And again, not only the payers, not only the hospitals, it's very much the whole healthcare system is not prepared for such an incident. And Rich was kind and asking my thoughts about a possible DLT or blockchain or enterprise blockchain and very much the hyperlegio solutions. And the first thing came my mind is pandemic management. I was involved in the emergency plans for IT organizations. It's very much the information flow at the end, evaluation and based on the evaluation also giving a response in different service levels. And very much also the case can be implemented in DLT, in enterprise blockchain with stakeholder management and recovery management all together. Mobilization and the recruitment of the additional resources, it already happened. The CPS Army is very much ready and there is also a division of the hospital hospitalization and they are supporting the hospitals and different small clinics around the country. It's Switzerland, it's surely a big support. And the third one is the information management. Again, not only in the hospitals but nationwide how it can be designed, how it can be architecture and how it can be implemented. And it is very much again the distributed ledger architecture and the evaluation of the 65 plus population where they are located and the test, immediate test. South Korea has a big success with wider testing and stopping the infection. This is very much the infected infects others. And the last one from the pandemic management the organization social emergency actions again integrated with the third one. Solution management, the vaccine that are already vaccine for influenza and I'm not quite sure that it's already tested that it can function against COVID-19. And so the clinical trial automation which we have already toolbox on soft tooth and fabric for patient recruitment and E-concept, it is very much innovation to accelerate the whole clinical trial. If you can imagine that a vaccine clinical trial takes normally six years, we need a solution sooner, I suppose. And the whole supply chain, you know what are the existing opportunities and how we can use for a pandemic which is unknown. And we can surely use the different stakeholders bringing them to each other with the governance with a smart contract and start if needed in a pandemic case, the blockchain solution. The findings, Europe reacted very much. Actually, European Union, there are already some possibilities, opportunities with various funds. And I think hospitals are also asking questions, what are the next opportunity and how we can improve our existing very much silo architecture and distributed information management. In data and process, a consolidation is very much needed for the next epidemies over for the next pandemies. Short, but not really short, reflection from my side, from Europe and from Switzerland. Thanks for listening. Excellent, thank you, Dennis. I appreciate it and I particularly appreciate sort of your sort of subjective view on how things are happening within the EU. A lot of what you're describing, I think is in many ways emulated here in the US. Of course, we tend to be very sort of US centric and so it's always great to sort of get an outside view, more of a global sort of view of, of course, this is no longer an epidemic, but it's a pandemic. And so that obviously implies that we really need to think at a global level. Any questions for Dennis? I do know, I'm sensitive to the fact that he does have to drop off the call, but any questions for Dennis? This is Wendy. I just wanted to thank Dennis for that great summary. It was very educational. Thank you for everything that you're doing. Thank you very much. Yeah, Dennis, this is Alex. Go ahead. Go ahead. I was going to ask him, I'm curious at the EU level and European levels, are there any conversations about the privacy security risks? I know that they've had a lot of lockdown over there historically to become more sensitive towards privacy than even we are here in the US. Is this causing any shifting and thinking of that, which you've heard about yet? And thank you for so much. You're very much welcome Alex. I'm not in the board of the European Union privacy agencies. The GDPR is very much present, but not in these corona days, not in these COVID days, 19 days, and it's a big issue. And there is certainly not a publication of the patients, not the names. The names are very much kept private, but surely, for example, in a small city next to Milano in Italy, Bergamo, is impacted heavily. Almost every day, more than 100 older people were killed by the virus, and their names were published in the papers with the consent of their relatives, surely, but it's surely not really a good report. I mean, great for the whole country publishing the names of these people, of these victims of the virus. And I mean, there is not a big incentive at the moment other than prevent the disease and prevent the effects of the virus. They are very much focused in that. And I don't see, I don't hear any incentive making the privacy more effective. Okay, thank you. You're welcome. Dennis, this is Talisia. Are they doing anything, how they're managing actually treatment? Again, I am not in the decision making groups. Nobody, even including yourself. And I hope for a speedy recovery, fully recovery for you and your wife. My personal reflection is very much personal and individual. It is that they should test from the start as much as many as possible, they didn't do that. And the next thing is, for example, if you get tested when you have fever over 38 centigrade, I don't know if Fahrenheit, and if you have really already severe coughing. And this is really instead of, it's not a preventive, it's very much reacting to the disease, to reacting to the virus instead of preventing. And if you are infected, the infection rate from one to the others is something over 150. And one infected person is infected more than 100 people, 100 others. So in the first weeks, when should they start with the testing, it will, the whole epidemic won't be pandemic. This is my impression, it's very humble and very subjective, but the state and the agencies were late in reacting. I hope it doesn't happen in the other countries, after Europe. And what are they doing for treatment? How are they managing that? It depends to the severity of the infection, if you are over 65 and don't have, let's say, over 38 plus centigrade fever and not blood coughing, et cetera, you stay at home and you take in the beginning as I am informed from my other friends, et cetera. This is the first treatment for the people who doesn't have severe symptoms or with the severe symptoms and over 65, et cetera, people are hospitalized as long as they have the infrastructure. And in the Italian part of Switzerland, there are already short of bats, short of devices. So they are mobilizing the army forces and this is surely a great help. But I cannot imagine, for example, in Africa or in different developing countries, this could be a solution. In Switzerland, there are still the resources for a smaller, relative smaller population with eight millions, but for a bigger population, it's more difficult. In Germany and in Austria, they have a better result, they have a better outcomes because they started earlier with the isolation and with also testing. And if you look into the numbers, it's not only not testing, it's I think because of testing, you have less fatalities and also infection numbers. Any other questions? So Dennis, and again, I'm sensitive to your need to leave, but I do have one sort of question that you just touched on. And it seems to suggest that different EU countries seem to be very, very different in their sort of a management and approach. Is there anything that you can sort of abstract from that? It almost sounds that Germany seems to have had sort of a much more pragmatic approach, much more direct and more immediate approach to sort of managing the virus. Is that sort of your takeaway? And what I'm looking for is maybe some sort of direction for this team, particularly, of course, I'm thinking here in the US, sort of best practices and in terms of where communication may be improved, how we might be able to sort of do better at what we're sort of struggling with today. I mean, in this concern, I speak as a private person and I can just compare the three speeches of the leaders, the German leader, Merkel and the Dutch prime minister and the British. And you can see three very much different approaches and at the end, three different results, outcomes. And I let you just, I mean, the Merkel was has spoken more data-driven and the Dutch minister and is a political leader, spoke Merkel, the German Chancellor and the Dutch spoke as a manager and the British in the beginning just spoke a kind of a natural selection. And there are three outcomes at the end and I let you appreciate what the outcomes could be with the further leader's speeches. I mean, we are dealing with IT, we are dealing with technology, we are dealing with the domain knowledge and I think we are very much also data-driven, fixed-driven and outcomes-driven and I think this is a good approach at the end. Okay, very interesting. So I appreciate that. I think it almost at the end of the day, it becomes a question of culture. And so it's interesting to me because as much as we sort of focus on technology at the end of the day, technology tends to be sort of implemented only by way of politics and sort of cultural sort of framework. So to me, it feels a little bit confirming to know that different people see things differently and that sort of rises all the way up through cultural values or cultural approaches to solving very, very similar problems. Well, thank you, Dennis. I appreciate it and again this really helps to add a little bit of color commentary to sort of what we're seeing here in the U.S. and it's always good to sort of get a sort of a faceted perspective and understanding of how people are treating this and where some of the sensitivities might lie as we sort of start thinking in terms of what solutions might look like to help alleviate the problems that are resulting from the COVID virus. So thank you. Thank you and take good care of yourselves and stay healthy. Thank you so much. Have a great day. Bye-bye. Okay. So I'm going to move now to Guillermo Diaz. Guillermo is one of our members for the HCCIG Healthcare Interoperability Subgroup. He's also the founder and director of La Nina Technologia and Ceresios, which is a company out of Mexico. Guillermo, you want to sort of take it from here. Did you want me to start up the PDF for it? Oh, yes. Yes, please, Rich. Thank you very much. And also I don't want to spend too much time. This is a briefing of what our government is communicating what is happening inside and outside. No. Thank you, Rich. Just basically this is the kind of information that we receive from our government. It's a kind of summary about what is happening outside Mexico, you know, by region and the way how this COVID-19 is moving ahead in all the world. So this is the first communication that we receive. Actually, let me tell you that this start two weeks ago. So I believe that was based on the pressure from other countries or neighbors from U.S. and Canada, of course, but also from organizations like World Wide Health Organization and so on. So they start moving with this kind of information. And if you go down, please, Rich, to the next slide. This is the information that we have locally, right? So basically what the government is doing, based on a toll-free number that they put on this process and our Epidemiological Intelligence Unit, they are tracking daily, two times daily, all the new cases by region, by city, and also they have a list of these cases. And they update it. And also this information is going directly to the World Wide Health Organization, right? So as you see, there is a similarity of what they are doing with the other countries and they are aligned. One of the things that I believe that we are lacking is, of course, the information about the hospitals and where to go. These 800 numbers is just to have a brief testing of a questioner, more than testing. You have to say what are your symptoms and if they believe that you are in risk, they just put it into the hospital that you have to go, right? The problem is that, of course, the lines has been collapsed some days at the beginning, but now they're increasing a little bit those lines. And finally, if you go to the next slide, please, Rich, this is the pressure that the Mexico government has been receiving since there were some polls that we didn't say anything, even the virus and the growing of the pandemic has been in other countries. So I believe that thanks to the pressure, we are reacting into the government. And then what I have to say is that we are under pressure because we have a health problem. For example, we have almost 11 million people with diabetes. And then if you see that the risk is growing, if you have another disease in combination with the current virus, there will be a huge problem held here in Mexico. So this is a brief summary. You can download this information, of course, and you can contact me if you need anything else. Thank you, Rich. Thank you. Any questions for Guillermo? Hi, Jim Mason. Looking at the data you have shown us from Mexico, I see different but similar data points from the U.S. from different sources and also other data sources as well. The two things that I can't see easily and are difficult to get as data points that would help understanding stuff is one, testing rates per million never show up anywhere. So when you look at the differences in the speed of infection of different countries, you can see that South Korea, particularly Japan, have done far better than say the U.S. has as an example. And you can't identify easily just from the data points we do have what causes those differences, that the infection rates are much slower. My suspicion is beyond maybe managing contact better. They also maybe are doing a more effective job of testing, but I don't know that because we don't have those data points. But certainly getting additional data points would help understand the speed and differences in how things spread. Correct. And this is one of the things that also as a citizen, we are arguing or we are talking about each other because one of the things is that now they are doing testing most into the private hospitals rather than the public hospitals. And I'm not sure. I mean, I don't have a very specific position, but I can tell you that I believe that the problem is that we were not prepared for this situation. And the budget was assigned to another kind of priorities at that time. So now the government is reacting to put more testing into the process, right? So we are just moving ahead, acquiring testing from the outside. And that's the reason why there are no so much information about positives or negatives into the process. Guillermo, this is Alicia. Are you having the same issues about getting the kids, the testing kids? Yes. And did you close your borders? Far as I know, the borders are not closed yet. There was a situation actually yesterday there was a meeting between Canada, Mexico and the U.S. talking about that. It's a pressure, of course, that if we don't perform well in this pandemic, there should be some other kind of actions from the other countries. But right now, we don't have borders closed. And there is, of course, a problem about getting testings into the public sector mainly. If you go into private, you can get that kind of testing approves. But in the public, it's a little difficult to get that. Yeah, because I'm from Colombia. And I know I'm not very following as close because I'm not there in the States. But like in Colombia right now, they didn't just close the borders. They are actually closing cities. In other words, they're closing, I don't know how they do it in Mexico, but we have departments. So like where Bogota is, they are actually closing to other cities. And they close the borders actually right now. I think it's as of Monday. No one can come in or get out of Colombia. They're closing to the world. But you and I know that in our countries, the wealthy and the better off will have more access to the kids and to, you know, like you were saying, the private hospitals. So are you seeing anything that is going to change that? Yeah, yeah, there is an initiative that we are going to not going into the public places, right? There is no closing, of course, between states, any access, of course, and they are not planning to do that. But there are some restrictions to go to public places like parks, like malls, et cetera. And it start next week, Monday next week. Because I think that for the, and this is, I've been talking to some of my friends in Europe. And one of the things that they are seeing is that in Latin American countries and in Europe, where families are closer and communities are closer, you know what I'm talking about. You can be with grandparents, parents, everybody's together. It's spreading faster because of that. Yeah. Excellent. Same as the case in Asian countries as well. I'm sorry, can you repeat that, please? Which I was just sharing my thoughts, you know, even from hearing from India and all as well. I mean, communities are much more closer compared to, you know, US. I mean, if this is happening here to the outbreak in some of those countries can be really dangerous. Yeah, in fact, I think it's really interesting. I don't know if any studies have been done, but I would imagine sort of cultural proximity. You know, maybe correlates pretty well with the, with the virus and I just haven't seen the data, but that this is just sort of, you know, kind of a gut thought on that. Right. Yeah, exactly. So I am just sort of sensitive to time and I do want to sort of shift over. Do we have any more questions for Guillermo before we move on? Okay. Well, thank you Guillermo. Again, great to get sort of your view from Mexico on the situation. And I think it helps to kind of color our understanding of what some of the issues are, what some of the problems that's happened to be. I do want to just take a quick pause. Heather, did you want to introduce part of your team on the call? Sure. I would, I would, those, those members of the consensus health team that have joined. If you, if you'd please just quickly introduce yourself like, you know, 10, 10, 15 second level intro. I did earlier at the beginning of the call. So I'm excited to be part of the team. Don't be shy. I'll try to get off the mute. Hi, this is Debbie Gucci. And I'm just joining the team as our. March 2nd and focuses on. Patient access and. Institutional data, et cetera, et cetera. I guess I should say I'm a director and excited to be part of the team. Thank you, Debbie. Anybody else. All right. I see our chief technology officer. Bill Glyme is on the line. Bill, are you, could you just introduce yourself real quick? He may have, he may have been. Called away, but away from keyboard. Yeah. He's our chief technology officer. And we're all looking forward to contributing. Excellent. Thank you, Heather. Appreciate it. So, so we've now heard from, from sort of several members around the world and also Alicia and ravish. Thank you for adding sort of your view as well. This, I think this is helpful because like I say, it sort of frames out kind of at a, at a much broader level outside of the US, particularly what some of the issues are. Just sort of in my note taking, I imagine there's sort of this, this workflow that we really want to be sensitive to. It's really about how do we manage information initially. And then what to do, which is kind of the next step of that, which is knowing that we have an issue within our country or borders, what do we do to prevent or slow down the virus. And then if you do happen to have it or believe you have it, where do you go? So I'm just starting to see this interesting sort of workflow here. And so I think Guillermo had made the comment about cues starting to happen. And yet there was a phone number that was supposed to sort of connect people so that they could get sort of care, more immediate care, more direction. And it didn't seem to quite work particularly well. And then there's a sort of longer term sort of management strategy that either in some places, and I'm thinking of what Dennis had said earlier, some countries seem to work very, very much better again culturally. And then some places it tended to be a little bit, a little bit more colored. So something to think about and what I'm going to walk us through. And then we're going to open it up just to the rest of the hour to just open conversation. I posted here quite a bit of funding opportunities. And again, this is more international. The rationale behind that is, and this is something that we've done in the past through the HEC. A lot of our members generally operate on funding requests. And so you notice that I posted some information about Canada. We just recently got some information as of yesterday for their rapid research funding opportunity as well as out of Ireland. They are working very closely with who. And so there's links that will take you to these different funding sites. Here in the U.S., there's of course quite a bit of information available. And of course we're biased because most of us are here in the U.S. And so feel free to sort of walk this. Brigham's and women's emergency department just two days ago issued a very broad email that I was in the receipt of asking for a call for a text-based platform solution for managing sort of that front line of need in their emergency emergency department. So the link is available to pursue that as well as some of our national organizations that tend to be very healthcare oriented, including the National Cancer Institute or NCI. And they work very closely with the NIH. And just in general, and I'll comment on this because I think some of our members are familiar with this, many of these funding opportunities are either grants where you effectively develop a proposal and pitch against that grant for funding or there are funding opportunities through small business, effectively small business loans or grants through SBIRs or STTRs. I suspect some of us, I know some of us have responded to some of those in the past. And I think, see, Stephen, I don't believe is on the call. He chairs are one of our subgroups on healthcare and operability. He and his team have worked, I believe, in SBIR in the past. These are openly available and we often through the HCC can parse these regularly. So I just want to make this information available. And then finally, one of the things that I found of a particular use, I had a colleague pass over to me. The UC Davis office of research is maintaining a regular link of COVID-19 funding opportunities through this link here. That seems to be getting updated regularly. So at minimum for anyone here in the states, I would suggest maybe taking a look there because they seem to be a great aggregator for regularly managed funding opportunities for the COVID virus. And then sort of finally, I just, this was really sort of for the sake of continuity. This is sort of what kicked us off several weeks ago that the US government had put together at that time a spending package which was very broad. And this was really the incentive for us to start to pursue this because with this spending package, we suspected that there would be funding opportunities that come from it. And then just recently, I want to say last week, we had another, what was defined as a relief package come together called the family's first coronavirus response act that is also liberating some different facilities within, and again, this is within the US. And so as we sort of think about potential solutions, some of these solutions may sort of work in very close proximity with some of these, these spending packages that have just come through. So with that said, any comments before we sort of get into sort of broader questions about how best to sort of tackle the problems facing us here? So Rich, you mentioned, you're mentioning a bunch of different things in the US relative to, I guess, tracking the virus and so on, different programs. One of the ones that's interesting this week, I think it was Monday or Sunday, the state of Massachusetts was the first state obviously to come up with what is called the Equivalent of Universal Healthcare, attempting to do that anyway, before we had the Obamacare stuff come out. And what was interesting is this week, they, what they did is they opened up access to in a sense everybody with lower incomes in the state flat out. So they just said all testing is free. If you're under a certain income level and everybody who is under that income level has the right to contact anybody, either at the state level or your own physician to, in a sense, request testing, you know, following whatever the protocol is. But they did say that all testing would be free along with a lot of other things as well, which is a huge change that even though the other states are all individually trying to solve problems as well, I don't, I'm not aware of any other state making that kind of an offer. So in fact, they automatically enroll you in free state healthcare based on your income level. You don't even have to apply anymore. They just look at your tax return and said, oh, you know, riches below the limit. So we're going to give you access automatically. Well, so, so, so thanks for that, Jim. So that's really interesting. So one of the, one of the thoughts that comes out of this, and what I'm hearing from some of the other folks that have talked is access to information. And that may be something that we may want to think about as, as a potential solution or one of several different solutions, which is how do we get information out to everybody? And what's the, what's the proper channel for sort of making that happen? What, what I'm hearing, did you say this is out of Massachusetts? Yeah, the governor of Massachusetts along with the healthcare administration here made all these changes. I think it was Monday morning, they declared it. So what I find particularly interesting about that is it, it isn't a passive, it doesn't sound to be a passive solution. What it sounds like is it's very active, meaning that they will automatically enroll you in this, the service. Yep. Yeah. I think it's had an income tax return last year that qualified. I believe you're automatically enrolled and that's it. Yeah. And what I find particularly, we're actually, to be honest, novel about that is that that would, that approach would alleviate a lot of the sort of issues that I think we're seeing, which is I just, you know, quote unquote, I just don't know what's going on. I don't know who to turn to. I don't know where to turn to to get the information for me. They do. Right. And like a lot of states, they do have a quote the state site on COVID-19. So when you go to all these state pages now, you always have the COVID-19 link right on the first page. But in this particular case, they do give you all that information about how, not just the standard, you know, here's the virus, here's the testing, here's what to do for treatment, but more, here's all the things the state has done to sort of help you out. So certainly if you're well aware income, and I don't know what percentage of it is, but it's fairly high cut in Massachusetts, a huge percentage of the state now, in a sense qualifies for free testing as well as, you know, I'll quote the information side. So how, so I'm, I'm just going to sort of think this through. So then how does the state identify that you did in fact, get tested? How does the, how do those results get managed? Well, we're doing, I know the state and it's not the only state, but a lot of the states now have these, the two things they're doing. One is they always have the, the standard state thing that says submitted a test to the state labs for validation. And a lot of states now are saying, no, we've opened up with private labs as well for testing. But the bigger thing is like a lot of the states, and I know Delaware does as too, is they have the drive-through tests now in certain locations. So basically all you do is you call your physician and say, gee, I think I have a fever. And, you know, if the physician agrees you have a fever, then you're potentially a candidate for a test. And once you have that, once they record the fact that the physician has approved you for a test, you go to a drive-through location, they drive through to swab you, and then in 24 hours the results come back. Assuming they have the test kits is the real issue there. So we've been constrained out, everybody's been constrained by the shortage of test kits, but the bigger thing is that the process makes sense because it's quick and it's easy. So at least a bunch of states have sort of tried to make that process simple. Excellent. So let me open this up. Anyone else on the call have some thoughts or ideas about what Jim is describing? Yes, Alfonso Govella from Medida. We all understand that social distances is a necessary medicine. But I think we have to understand, and that's what we're living in Mexico, that this medicine, much needed, has secondary effects. And the secondary effects are related to economics and social life. It's great what Massachusetts is doing to test for free. But I see it here in my city. People cannot stop going out to work because if they do, they cannot eat that day. So how can we complement the social distancing with alternative measures that helped poor people at least 50% in our country survive personally, socially, and economically? Yeah, the socially part. I don't have the answer to that at all. I'll say is we have ways to obviously connect socially over different types of media, which is I guess a plus. But you're right, there's big restrictions there that can't be overcome with social distancing. But on the economic side again, you're right, look around the world and you'll see different responses economically. And while the US is trying to put together different ones now on our side of the fence, there's no question that I'd say, at least in the US I can speak, and say the federal government coordinates with states and large private companies on how to handle natural disasters. So they have a whole protocol for this. But all the protocols were focused around the theory that the disaster is quick. Something like a nuclear bomb goes off, an earthquake happens, you know, whatever, and that huge things of society are immediately affected by that. And the theory was that you have this impact that happens fairly quickly, and that from that point on, you have to say, how are we going to restore services and wall types? So that planning actually does go on. The problem is this is not the same because it isn't like a nuclear bomb or an earthquake where it happens relatively quickly. This is a slow-moving thing. And back to your point, nobody I don't think has really a solid plan on the economic side on how do you help alleviate that problem, for sure. So we can see everybody talking about it, but there certainly wasn't, at least in the US, any kind of a real plan for that in place prior to this issue coming up. And that is an enormous issue. So it's not about just saying, flatten the curve and stop the virus in the next 30 days or 60 days from spreading, which is a great thing. The bigger thing is, you're right, you look beyond that and say, well, okay, if this isn't solved in 30 to 60 days, what happens, what parts of the economy don't come back kind of things? It goes longer. And so those are all new questions, I think, that we're looking for answers. Thank you. Thank you, Alfonso. You bring up an interesting point, and there's a little bit of an analog, sort of where I live, and we live somewhat close to one of the Boeing plants, where they build some of the three sevens and triple sevens. And to your point, we are getting reports that a lot of the factory workers are in a very similar state where if they don't work, they have very difficult time financially. So I think the driver then is that they continue to work when perhaps they shouldn't be. And in fact, we're just now getting reports that there are indications of the virus within Boeing. And so it's a very accurate sort of statement to say, there are people that absolutely need to work. And so they must continue to go in and work the lines. And if they don't, it really threatens their livelihood and their family. And of course, their priority has to be family first in that respect and community second, because it becomes really a question of survival, whether it's physical survival or financial survival. And so we really need to think in terms of how do we offset this very, very thin line so that people can either have that knowledge or information to make the right decisions or have resources available so that they can sort of substitute their requirement to go in to work and potentially infect others, which is part of the reason why this virus has done the extent of the damage. I think part of it is just a lack, general lack of understanding and substitute that with something that people can recognize that it's really got to be community first knowing that their family is protected or that they have some level of financial protection. So that they can really focus on community. Anybody else? I'd like to hear from some new names if possible, just to sort of keep the momentum going. And I'd really like to continue to get sort of a facet of an understanding of where people are coming from, what their thoughts might be relating to this. Oh, it's awfully quiet. All right. I'm going to call out Brian. I was just unmuting my mic. Yeah. We go. Thank you. Hi, everyone. Brian Bellendorf, executive director at Hyperledger. You know, obviously we as an organization are, you know, are I think finding our footing and helping our employees get adjusted to the new reality. But also and continuing forward, you know, we had a great hyperledger global form at the beginning of the month. And to have that happen right at the tail end of what seems now like an eon ago, right? Or some of their era, you know, is, and then to shift immediately into everything shutting down. It's pretty, you know, whiplashy for, I think a lot of us now, you know, but all of us work from home already. The adjustment, you know, from that hasn't been so bad. But obviously, you know, everyone in our community, their mind has been elsewhere now. Now people are starting to adjust. Now people have kind of gotten kind of realized it's a very exciting reality. We'd like to now start to think about, are there things that we can do, you know, through the SIG, no doubt, but through other efforts to help our members and the broader healthcare community and the broader DLT community find some way to construct something together, right? That would be helpful. I am very, very wary of saying we have a hammer and there must be some nails around here somewhere. But I'm sure there are folks of you out there who are looking at different projects, different calls to action. If there is a way where sharing of source code, which is kind of our first and most important skill, and sharing of standards, sharing of knowledge, but actually building software together, if there's something we can do to be helpful on that front, we'd be very eager to know. There are a couple things, a couple of domains that I'm tracking. People out there with good ideas, but I'm really eager to find people on the ground or some combination of funding, but more importantly, actual need, actual frontline folks who say, this is something to be helpful to us before jumping into something. So folks out there have that kind of thing. We could either hear about it now or ping us separately. We'll try to find a couple of other structured ways to collect those kinds of opportunities. But the door is open, so please let us know if there's something you think we can do to help. Thanks, Brian. Yeah, and this is an ongoing issue, obviously. We continue the conversation. Today's is really sort of the kickoff. We will continue to sort of focus on trying to manage how do we approach and sort of solve some of the problems that come out of the COVID-19 virus. Just sort of looking ahead and we are coming up to the top of the hour. In the next two weeks, we'll continue this discussion. This will be a primary focus really going forward for quite some time, I suspect. I can say that Dennis, who we heard from earlier out of Switzerland who also chairs the HEC patient subgroup, he and his team have an E-consent solution that they've been working on. I believe John Walker, John are you on the call? I think you're on your part of that team. So it's really a great solution that they're continuing to move forward on. John, very, very briefly, did you want to sort of provide a little bit of a status on where you are with the patient subgroup? Right, so we're doing two POCs that look, basically we're focused on consent, we're on the front end of clinical trial and those are, we've got some forms. We're probably still four weeks away from having our POC complete. The goal being to have some simple forms that would demonstrate representative data used for E-consent and then compare how that data is both collected and shared, written to, distributed ledger on both sawtooth and fabric. So those are works in progress, but we're certainly interested in applying those and gaining resources to apply those to another pattern or permutation potentially in this space. But those activities are still ongoing. Thanks, John. Yeah, and then I think our next meeting, we're going to try to get Patty Buendia. She's active with Erica's team and they're developing around use cases. And I believe Patty has a solution that she wants to share as well. So we'll be catching that in two weeks, which is our next meeting. And again, as we close out this hour, we have these regular meetings every two weeks, seven o'clock Pacific time on the same channel. So really, oh, I'm sorry, go ahead. Sorry, this is Ravish. I just wanted to quickly, you know, make an announcement, announcement regarding the payer subgroup as well. I think we sent out a use case that we are going to be starting on for the POC. So I just wanted to request anyone who is interested in, it's around prescription management and anyone who is interested in joining our peer subgroup to participate in the POC as well. Yeah, they're most welcome. Thanks, Ravish. Okay. Well, thanks everyone for your participation. We are at the top of the hour. We're out of time. We really look forward to seeing you in two weeks. In the meantime, feel free to access our rocket chat channel. We've got our healthcare SIG is set up over there for, for regular communication. Otherwise continue to monitor our listserv. We'll continue this discussion going forward. Thanks everybody. Take care. Have a great weekend. Be safe. Thank you. Thank you. Thank you. Stay healthy.